Company patents
UNIVERSITÄT HEIDELBERG
UNIVERSITÄT HEIDELBERG's patent strategy shows a strong, albeit fluctuating, focus on Pharmaceutical Preparations (51.0% of portfolio) and Peptides & Proteins (37.3%), with both categories experiencing significant year-over-year growth in 2025 (Pharmaceutical Preparations +66.7%, Peptides & Proteins +133.3%) before a sharp decline so far in 2026. Interestingly, while core pharma categories saw a dip in 2026, there's an emerging focus on Nanotechnology and Sterilization & Biocompatible Materials, both showing 2 patents so far in 2026 after no activity in prior years, indicating a potential diversification into materials science for medical applications.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
51 US filings (since 2023) · 12 categories · 20 themes
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Computational methods and systems for analyzing biological data (e.g., genomic, proteomic, clinical) to diagnose diseases, predict patient prognosis, assess treatment response, or stratify patients for therapy.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Implantable devices designed to repair, replace, or assist the function of blood vessels or heart structures, including stents, valves, and annuloplasty rings.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.
Computational techniques and algorithms for processing, aligning, and interpreting raw biological sequence data (DNA, RNA, protein), including identifying genetic variations, classifying organisms, or predicting sequence attributes.
Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.
Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.
Patents
Showing 1-10 of 83